Analysts at HC Wainwright cut their FY2024 earnings estimates for shares of Mawson Infrastructure Group in a note issued to investors on Tuesday, November 26th. HC Wainwright analyst K. Dede now ...

Alector, Inc. (NASDAQ:ALEC – Free Report) – HC Wainwright issued their Q1 2025 EPS estimates for shares of Alector in a ...

Fintel reports that on November 25, 2024, HC Wainwright & Co. initiated coverage of Sarepta Therapeutics (LSE:0L35) with a Sell recommendation. As of November 21, 2024, the average one-year price ...

HC Wainwright & Co.：重申Intellicheck(IDN.US)评级，由买入调整至买入评级, 目标价由4.00美元调整至4.00美元。 Intellicheck（IDN.US）公司简介：Intellicheck Inc 是一 ...

HC Wainwright & Co.：重申WidePoint(WYY.US)评级，由买入调整至买入评级, 目标价由7.00美元调整至7.00美元。 WidePoint（WYY.US）公司简介：WidePoint Corp是一家技术 ...

H.C. Wainwright lowered the firm’s price target on Splash Beverage (SBEV) to 50c from $1 and keeps a Buy rating on the shares ...

Fintel reports that on November 25, 2024, HC Wainwright & Co. initiated coverage of Sarepta Therapeutics (NasdaqGS:SRPT) with a Sell recommendation. As of November 21, 2024, the average one-year ...

To access the live webcast of the fireside chat, please visit: https://investor.arbutusbio.com/events-presentations. An archived replay of the webcast will be available on the Arbutus website for a ...

Fintel reports that on November 26, 2024, HC Wainwright & Co. downgraded their outlook for Poseida Therapeutics ...

HC Wainwright sets an $18 target on Vanda Pharmaceuticals amid a 30% discount to cash reserves. Vanda's portfolio could reach key clinical and regulatory milestones within 6–18 months.

HC Wainwright initiated coverage on Vanda Pharmaceuticals, Inc. (NASDAQ:VNDA), a commercial-stage biopharmaceutical firm primarily focusing on neurological and neuropsychiatry disorders.